“ Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...

New Haven biotech Alexion Pharmaceuticals Inc. will partner with a startup in the Netherlands on a new drug to treat degenerative brain disorders. Alexion on Monday announced a deal with ...

As Kira Pharma shepherds two more programs toward the clinic, the complement-focused biotech is bolstering its leadership team with a trio of biopharma veterans, including a pair of Alexion alums. Its ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Alexion Pharmaceuticals will acquire New Haven-based pharmaceutical company Achillion Pharmaceuticals for an anticipated $930 million, the companies announced last week. The two companies develop rare ...

The complement system is designed to kill pathogens through a signal cascade that results in cell lysis, removal of the pathogens through phagocytosis, and alerting other immune system cells to help ...

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines.

For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...

The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral ...

“Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...